FIGURE 7.

Pharmacokinetics and pharmacodynamics of dexanabinol and bortezomib in a MM1.S multiple myeloma mouse model. Model predicted mouse plasma concentrations of (A) 1 mg/kg of bortezomib administered on Days 1, 5, 8, 12, 15, and 19 and (B) 10 mg/kg of dexanabinol administered on Days 1, 5, 8, 12, and 15. (C) Pharmacodynamics of bortezomib and dexanabinol on MM1.S tumor volume in SCID mice. Tumors were grown to approximately 100 mm³ prior to drug administration. Mice (n = 20) were divided into four treatment groups: treatment naïve (black), dexanabinol (blue), bortezomib (red), and their combination (purple). Bortezomib and dexanabinol were administered IP twice weekly (1 and 10 mg/kg). Tumor volume measurements and pharmacodynamic model fitted profiles are displayed as solid markers and dashed lines. Asterisks indicate statistical significance from control (corrected p value < 0.5), which were obtained via multiple t-tests with Holm-Sidak Bonferroni correction (GraphPad Prism v7.04).